E E Vink1, W L Verloop2, L Siddiqi3, L J van Schelven4, P Liam Oey5, P J Blankestijn6. 1. Department of Nephrology, University Medical Center Utrecht, The Netherlands. Electronic address: e.e.vink-2@umcutrecht.nl. 2. Department of Cardiology, University Medical Center Utrecht, The Netherlands. Electronic address: w.l.verloop@umcutrecht.nl. 3. Department of Nephrology, University Medical Center Utrecht, The Netherlands. Electronic address: l.siddiqi-2@umcutrecht.nl. 4. Department of Medical Technology and Clinical Physics, University Medical Center Utrecht, The Netherlands. Electronic address: l.j.vanschelven@umcutrecht.nl. 5. Department of Nephrology, University Medical Center Utrecht, The Netherlands. Electronic address: p.l.oey@umcutrecht.nl. 6. Department of Nephrology, University Medical Center Utrecht, The Netherlands. Electronic address: P.J.Blankestijn@umcutrecht.nl.
Abstract
OBJECTIVE: The rationale of percutaneous renal denervation (RDN) is based on extensive studies suggesting that renal nerves contribute to hypertension and that they comprise a sensible treatment target. Muscle sympathetic nerve activity (MSNA) is considered to be one of the few reliable methods to quantify central sympathetic activity. The aim of this current study is to determine the effect of RDN on MSNA in a standardized fashion. METHODS: MSNA was determined in 13 patients before and 6months after RDN. Anti-hypertensive medication was stopped before MSNA. If cessation of medication was considered unsafe, a patient was instructed to use the exact same medication on both occasions. RESULTS: Ten sets of MSNA recordings were of good quality for analysis. Mean age was 57 ± 3 years and mean eGFR was 85 ± 18 mL/min/1.73 m(2). MSNA was determined twice during a medication free interval in 5 patients; 1 patient used the exact same medication twice, and 4 patients used different drugs. Mean BP changed from 206 ± 7 over 116 ± 4 mmHg, to 186 ± 6 over 106 ± 3 mmHg, 6 months after RDN (p=0.06 for systolic BP, p=0.04 for diastolic BP). Mean resting heart rate did not change (p=0.44). MSNA did not change after RDN: 37 ± 4 bursts/min and 43 ± 4 bursts/min (p=0.11) at baseline and after RDN, respectively. In the 6 patients with standardized medication use during the MSNA sessions, results were comparable. CONCLUSIONS: Treatment with RDN did not result in a change in MSNA. Changes in BP did not correlate with changes in MSNA.
OBJECTIVE: The rationale of percutaneous renal denervation (RDN) is based on extensive studies suggesting that renal nerves contribute to hypertension and that they comprise a sensible treatment target. Muscle sympathetic nerve activity (MSNA) is considered to be one of the few reliable methods to quantify central sympathetic activity. The aim of this current study is to determine the effect of RDN on MSNA in a standardized fashion. METHODS: MSNA was determined in 13 patients before and 6months after RDN. Anti-hypertensive medication was stopped before MSNA. If cessation of medication was considered unsafe, a patient was instructed to use the exact same medication on both occasions. RESULTS: Ten sets of MSNA recordings were of good quality for analysis. Mean age was 57 ± 3 years and mean eGFR was 85 ± 18 mL/min/1.73 m(2). MSNA was determined twice during a medication free interval in 5 patients; 1 patient used the exact same medication twice, and 4 patients used different drugs. Mean BP changed from 206 ± 7 over 116 ± 4 mmHg, to 186 ± 6 over 106 ± 3 mmHg, 6 months after RDN (p=0.06 for systolic BP, p=0.04 for diastolic BP). Mean resting heart rate did not change (p=0.44). MSNA did not change after RDN: 37 ± 4 bursts/min and 43 ± 4 bursts/min (p=0.11) at baseline and after RDN, respectively. In the 6 patients with standardized medication use during the MSNA sessions, results were comparable. CONCLUSIONS: Treatment with RDN did not result in a change in MSNA. Changes in BP did not correlate with changes in MSNA.
Authors: Marat Fudim; Asher A Sobotka; Yue-Hui Yin; Joanne W Wang; Howard Levin; Murray Esler; Jie Wang; Paul A Sobotka Journal: Curr Hypertens Rep Date: 2018-05-01 Impact factor: 5.369
Authors: Erin J Howden; Cara East; Justin S Lawley; Abigail S L Stickford; Myrthe Verhees; Qi Fu; Benjamin D Levine Journal: Am J Hypertens Date: 2017-06-01 Impact factor: 2.689
Authors: Jens Tank; Karsten Heusser; Julia Brinkmann; Bernhard M Schmidt; Jan Menne; Johann Bauersachs; Hermann Haller; André Diedrich; Jens Jordan Journal: J Am Soc Hypertens Date: 2015-07-31
Authors: Hitesh C Patel; Carl Hayward; Vassilis Vassiliou; Ketna Patel; James P Howard; Carlo Di Mario Journal: Integr Blood Press Control Date: 2015-12-03